Direct oral anticoagulants versus aspirin for venous thromboembolism prophylaxis after orthopedic surgery.


Journal

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
ISSN: 1535-2900
Titre abrégé: Am J Health Syst Pharm
Pays: England
ID NLM: 9503023

Informations de publication

Date de publication:
17 May 2019
Historique:
pubmed: 18 4 2019
medline: 21 1 2020
entrez: 18 4 2019
Statut: ppublish

Résumé

The risks of venous thromboembolism (VTE) and bleeding with direct oral anticoagulants (DOACs) and aspirin for thromboprophylaxis after orthopedic surgery were studied. A single center, retrospective study was conducted to examine patients who underwent a major orthopedic surgery from 2011 to 2015. The primary endpoint evaluated was the net clinical outcome of bleeding and thrombosis rates between the DOAC and aspirin groups. Secondary endpoints included bleeding rates, thrombosis rates, transfusion rates, and 90-day readmission rates. The primary endpoint was analyzed using adjusted logistic regression model with propensity score added as an independent variable. A total of 420 patients were included in this study. The proportion of patients with composite primary outcome was similar between the groups (12.9% and 13.3%, in the DOAC and aspirin groups, respectively; p > 0.5). VTE events were numerically lower in the DOAC group, but the result was not statistically significant. Readmission due to VTE or bleeding and bleeding events were also similar between the groups. The DOAC group had a higher proportion of blood transfusions of at least 2 units of blood postoperatively compared with the aspirin group (p = 0.04). No difference in net clinical outcome was observed in patients who received a DOAC or aspirin for VTE prophylaxis after major orthopedic surgery.

Identifiants

pubmed: 30994169
pii: 5474309
doi: 10.1093/ajhp/zxy080
doi:

Substances chimiques

Anticoagulants 0
Aspirin R16CO5Y76E

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

S55-S60

Informations de copyright

© American Society of Health-System Pharmacists 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Tianrui Yang (T)

Houston Methodist Hospital, Houston, TX.

Michelle Murillo (M)

Houston Methodist Hospital, Houston, TX.

Aisha Vadhariya (A)

Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX.

Allison Wilson (A)

Houston Methodist Hospital, Houston, TX.

David Putney (D)

Houston Methodist Hospital, Houston, TX.

James Muntz (J)

Houston Methodist Hospital, Houston, TX.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH